Radius Health is a biopharmaceutical company focused on developing and commercializing endocrine and other therapeutics. Co.'s commercial product, TYMLOS (abaloparatide) injection is for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Co. is developing an abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis. Co.'s wholly-owned subsidiary, Radius Pharmaceuticals, Inc., owns certain assets related to formulations of cannabidiol related to the oral administration of a solution of cannabidiol for therapeutic use in humans or animals (RAD011). The RDUS stock yearly return is shown above.
The yearly return on the RDUS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RDUS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|